Summary & Overview

HCPCS G9894: Androgen Deprivation Therapy with External Beam Radiotherapy to Prostate

HCPCS Level II code G9894 designates the provision of androgen deprivation therapy (ADT) in combination with external beam radiotherapy (EBRT) directed to the prostate. This code captures a multimodal treatment approach commonly used in patients with localized or locally advanced prostate cancer where combining systemic hormonal therapy with targeted radiation improves clinical outcomes. Nationally, accurately capturing combined ADT and EBRT is important for clinical documentation, quality measurement, and appropriate reimbursement for integrated oncology care.

Key payers referenced include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code’s clinical context and service setting, along with benchmarking and policy-oriented content where available. The publication outlines how the code is used on service lines involving radiation oncology and hospital outpatient settings, clarifies typical sites of service, and summarizes common modifier usage and payer considerations when present.

This summary equips billing managers, oncology administrators, and health policy analysts with a clear understanding of what G9894 represents, why its use matters for care coordination and billing integrity, and where to look for further detail on coverage and claims handling. Data not available in the input is noted where applicable in the full report.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareG9894HCPCS Level IIandrogen-deprivation-therapyexternal-beam-radiotherapyprostate-cancerradiation-oncologyoncology-billingmultimodal-therapy

Billing Code Overview

HCPCS Level II code G9894 describes androgen deprivation therapy prescribed or administered in combination with external beam radiotherapy to the prostate. This service represents the use of systemic hormone therapy alongside radiation treatment targeted at the prostate gland.

Service type: Combined systemic androgen deprivation therapy with external beam radiotherapy
Typical site of service: Radiation oncology departments, hospital outpatient departments, and freestanding radiation therapy centers

Clinical & Coding Specifications

Clinical Context

A typical patient is a 68-year-old man diagnosed with intermediate- to high-risk localized prostate adenocarcinoma who is scheduled to receive definitive external beam radiotherapy (EBRT) to the prostate. Androgen deprivation therapy (ADT) is prescribed and administered in combination with EBRT to improve oncologic outcomes by suppressing testosterone-driven tumor growth during radiation. The clinical workflow includes urology or medical oncology confirmation of diagnosis and staging, baseline labs (PSA, testosterone), informed consent, documentation of indication for combined therapy in the medical record, scheduling of ADT (either as a surgical orchiectomy or, more commonly, injectable luteinizing hormone–releasing hormone agonist/antagonist or oral androgen pathway agent), coordination with radiation oncology to time initiation of ADT typically 1–3 months before or concurrent with EBRT, administration of the ADT in the outpatient infusion clinic or office, coders assigning billing code G9894 to indicate ADT prescribed/administered in combination with external beam radiotherapy to the prostate, and documentation of any related procedures, complications, or medical necessity. Typical site of service is outpatient oncology clinic, radiation oncology clinic, or ambulatory infusion/office setting. Common clinical staff involved include urologists, radiation oncologists, medical oncologists, nurse practitioners, registered nurses, and oncology pharmacists. Payors commonly involved include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare for authorization and reimbursement workflows.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	When work, time, or technical difficulty of ADT administration is substantially greater than usual (documentation required).
`23`	Unusual anesthesia	If unusual anesthesia is required for a procedure related to ADT administration (rare for injections; documentation required).
`52`	Reduced services	When ADT administration or a related service is partially reduced or not completed as planned.
`53`	Discontinued procedure	When an ADT procedure is started but discontinued due to patient condition or safety concerns.
`54`	Surgical care only	If a surgeon provides only the surgical portion (e.g., orchiectomy) and other postoperative care is billed separately.
`55`	Postoperative management only	When another provider bills only postoperative care after surgical ADT (orchiectomy).
`56`	Preoperative management only	When another provider bills only preoperative evaluation prior to surgical ADT.
`62`	Two surgeons	When two surgeons with different specialties perform distinct portions of a surgical ADT procedure (e.g., complex orchiectomy).
`AS`	Ambulatory surgical center (facility)	To indicate services furnished in an ASC when applicable.
`QK`	Medical direction of two, three, or four concurrent anesthesia procedures	When the physician medically directs multiple anesthesia practitioners during an ADT-related procedure requiring anesthesia.

Taxonomy Code	Specialty	Notes
`207X00000X`	Urology	Urologists evaluate prostate cancer and may perform orchiectomy or coordinate ADT.
`2084P0800X`	Radiation Oncology	Radiation oncologists prescribe and coordinate ADT with EBRT treatment planning.
`2086S0120X`	Medical Oncology	Medical oncologists prescribe systemic ADT agents and manage hormonal therapy.
`363LP0800X`	Registered Nurse	RNs administer injections and manage patient education and infusion site care.
`363A00000X`	Nurse Practitioner	NPs manage ordering, monitoring, and administration of ADT in outpatient settings.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C61`	Malignant neoplasm of prostate	Primary diagnosis for which ADT in combination with EBRT is commonly indicated to improve local control and survival in intermediate- and high-risk disease.
`N40.0`	Benign prostatic hyperplasia with lower urinary tract symptoms	May coexist with prostate cancer; influences symptom management but not a direct indication for ADT with EBRT.
`D07.5`	Carcinoma in situ of prostate	Early malignant lesion; clinical relevance depends on staging and multidisciplinary treatment decisions.
`R97.20`	Elevated prostate specific antigen (PSA), unspecified	Biochemical indicator prompting diagnostic evaluation, treatment planning, or monitoring response to ADT and EBRT.
`Z85.47`	Personal history of malignant neoplasm of prostate	Relevant for surveillance and decisions about salvage therapies including ADT plus radiation.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`54100`	Orchiectomy, simple (unilateral or bilateral)	Surgical ADT option for permanent androgen suppression; may be performed instead of medical ADT prior to or with radiation planning.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug)	Office administration of injectable ADT agents (e.g., leuprolide, goserelin) given concurrently with radiation therapy.
`96401`	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal (single or initial substance/drug) — (Note: hormonal agents may be billed similarly per payer rules)	Used by some practices to report parenteral hormonal agent administration per payer guidance when applicable.
`77295`	Therapeutic radiology plan, complex (IMRT doses, volume definition, or image guidance)	Advanced external beam radiotherapy planning codes commonly billed by radiation oncologists in the same episode of care when ADT is combined with EBRT.
`77427`	Radiation treatment management, 5 treatments	Radiation oncology management code used during the course of EBRT delivered in combination with ADT.